We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy

News

Stay updated on Click.mAb. news, technology progress, and industry insights

Clickmab at the 2026 Biophysics Congress: Sharing New Explorations in Epitope-Specific AI De Novo Antibody Design

Events

August 5, 2026

Clickmab at the 2026 Biophysics Congress: Sharing New Explorations in Epitope-Specific AI De Novo Antibody Design

The 2026 Biophysics Congress was recently held in Hainan, where Clickmab presented its proprietary Click.mAb. AI antibody R&D platform and shared its technical explorations in epitope-specific de novo design, affinity maturation, and humanization. During the congress, Zhang Hong, academician of the Chinese Academy of Sciences and president of the Chinese Biophysical Society, visited Clickmab's booth for an in-depth exchange.

Read Full Article

Academic Exchange | Visit to Hangzhou Institute of Medicine Chinese Academy of Sciences: Exploring New Frontiers in AI Antibody Design

Events

July 23, 2026

Academic Exchange | Visit to Hangzhou Institute of Medicine Chinese Academy of Sciences: Exploring New Frontiers in AI Antibody Design

Recently, Dr. Tianyuan Wang, CEO of Clickmab, conducted a special exchange session at the Hangzhou Institute of Medicine Chinese Academy of Sciences, delivering a keynote titled "Epitope-Specific AI De Novo Antibody Design for Antibody Drug R&D — Technical Principles, Current Applications, and Breakthrough Strategies." He shared the latest explorations of AI in antibody drug R&D and engaged in in-depth discussions with researchers on new trends, methods, and practical applications of AI-empowered biomedical R&D.

Read Full Article

Two Days at AsiaBIO: The 5 Questions We Answered Almost Every Day

Events

July 13, 2026

Two Days at AsiaBIO: The 5 Questions We Answered Almost Every Day

On July 9–10, the AsiaBIO 2026 Innovation Summit (North China) was held in Beijing. Clickmab presented the Click.mAb. multi-agent AI antibody R&D platform, with CEO Dr. Tianyuan Wang delivering a keynote. Here we summarize the five questions we were asked most often on-site, along with our thoughts.

Read Full Article

CDR Diversification Now Available: One Great Antibody, Unlimited Design Possibilities

Platform Updates

July 1, 2026

CDR Diversification Now Available: One Great Antibody, Unlimited Design Possibilities

To address the challenges of low efficiency and high randomness in CDR diversity library construction, Click.mAb. has officially launched CDR Diversity Engineering, using structure-guided design to help R&D teams obtain high-quality candidate libraries that balance diversity and developability.

Read Full Article

Events

June 26, 2026

Guangzhou Laboratory Academic Exchange: Dr. Tianyuan Wang Shares AI Antibody Design R&D Practice

Dr. Tianyuan Wang, CEO of Clickmab, delivered a keynote at Guangzhou Laboratory, sharing the latest R&D practices and progress in AI-driven de novo antibody design, directed optimization, and the multi-agent platform.

Read Full Article

Events

June 11, 2026

From "Screening" to "Design": How AI Is Reshaping Antibody Drug R&D — "AI × Frontier Protein Technologies" Summit Successfully Held

On June 11, 2026, the "AI-Driven Future: AI × Frontier Protein Technologies for Challenging Targets" summit co-hosted by Clickmab, Kactus Biosystems, and Sanyou Bio was successfully held in Shanghai, exploring new AI-driven antibody R&D paradigms and industry practices.

Read Full Article

Events

May 25, 2026

At BioPlus, Clickmab Uses AI to Decode a $2B Upfront TCE Molecule

On May 21-22, the "Antibody 3.0 | 2026 BioPlus Antibody Annual Conference" hosted by BioPlus Partners was successfully held in Suzhou. As a Gold Sponsor, Clickmab showcased its AI-driven antibody drug R&D platform and delivered a keynote in the oncology forum, exploring new trends, models, and opportunities in next-generation antibody R&D.

Read Full Article

Events

May 11, 2026

Clickmab at CBA-China 2026: AI-Driven Antibody R&D Practice and Exploration

Clickmab showcased its multi-agent AI antibody design platform Click.mAb. at CBA-China 2026, sharing the latest practices in de novo design, affinity maturation, humanization, and R&D collaboration.

Read Full Article

Company

March 2, 2026

Clickmab Completes Seed+ Funding Round Led by Hualan Shares

Led by Hualan Shares with follow-on investment from XtalPi and Xichuangtou, this round will accelerate Click.mAb. platform iteration and proprietary data flywheel building.

Read Full Article

Partners

June 4, 2025

Clickmab AI Platform Supports Major APJ Collaboration Between Jikang Bio and BioAge

Jikang Bio and BioAge reached a strategic preclinical collaboration on a novel APJ agonist antibody, with Clickmab's AI platform playing a key role in discovery and optimization.

Read Full Article

Events

May 6, 2025

Clickmab Wins 2025 Chinese Antibody Society Poster Presentation Award

Clickmab's NAVIGATOR workflow for GPCR agonist antibody optimization won the Chinese Antibody Society Poster Presentation Award again.

Read Full Article

Shape the Future of Antibody Therapeutics Together

Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.

Get Started Contact Us